$SGMO Sangamo therapeutics clean setup

support held past few weeks around $15.70. declining volume on sell-off. owns many patents and has deals to bring many CRISPR style medications through development testing and sales. strong revenue growth in a growing and increasingly accepted medical field. potential breakout target of $29. Biotech stocks are high risk as they depend on experiment success or failure (and success or failure of the competitors). failure means the sales expectations get wiped out instantly and so does the stock price. positive results boost sales and the value of the stock reflects this with rapid and dramatic price increase (magnified by the significance of the medications/treatments to investors perception).